Loading clinical trials...
Loading clinical trials...
The purpose of this study is to learn more about both HIV-1 infection and advancing age, and their association with increased risk of serious infection and impaired response to the Prevnar 13 vaccine.
After being informed about the study and potential risks, patients will be screened to determine eligibility for the study and consented. Patients who meet eligibility requirements will be immunized with PCV 20. HIV-infected adults will be tested prior to and after vaccination by blood, nasal filter paper, and stool samples to characterize mucosal and systemic antibody responses . HIV-uninfected control adults will be tested at vaccination and post vaccination to characterize mucosal and systemic antibody responses .
Age
21 - 75 years
Sex
ALL
Healthy Volunteers
Yes
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, United States
Start Date
January 18, 2017
Primary Completion Date
January 1, 2027
Completion Date
January 1, 2028
Last Updated
July 15, 2024
100
ESTIMATED participants
Prevnar-13
BIOLOGICAL
Lead Sponsor
VA Eastern Colorado Health Care System
NCT07071623
NCT07115901
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07236905